In Erin's case, we don't hear of any upcoming credits or bonus sales going on for the drug cost. The cost is the cost. However, in our disease case there is current research going on with, I believe, three other companies to produce other drugs that look promising to be cheaper. They're just not available yet. Down the road they may work just as well as the eculizumab but eculizumab is the only one currently available.
On October 30th, 2018. See this statement in context.